Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Heart FailureCardiometabolic SyndromeCancer DiagnosisCardiovascular DiseasesHealthy Volunteers
Interventions
DRUG

Hyperpolarized 13C-pyruvate

Hyperpolarized 13C-pyruvate is injected intravenously at a dose of 0.43 mL/kg body weight, and at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second when the patient is already in the MRI scanner

Trial Locations (1)

169609

RECRUITING

National Heart Centre Singapore, Singapore

All Listed Sponsors
collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

lead

National Heart Centre Singapore

OTHER